US Patent

US8987323 — Crystalline form of benzylbenzene SGLT2 inhibitor

Composition of Matter · Assigned to Theracos Inc · Expires 2032-05-14 · 6y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline forms of a compound that inhibits sodium-dependent glucose cotransporter SGLT2.

USPTO Abstract

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Drugs covered by this patent

Patent Metadata

Patent number
US8987323
Jurisdiction
US
Classification
Composition of Matter
Expires
2032-05-14
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Theracos Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.